IGF1 and breast carcinoma: These pathways include PDGF signaling (BH-FDR = 0.00012), estrogen-dependent breast cancer signaling (BH-FDR = 0.00068), JAK/Stat signaling (BH-FDR = 0.00055), IGF-1 signaling (BH-FDR = 0.00089), glucocorticoid receptor signaling (BH-FDR = 0.0017), VEGF signaling (BH-FDR = 0.0012) and BMP signaling pathway (BH-FDR = 0.0025), suggesting that these pathways are altered in the earliest stages of the disease.